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To establish whether existing mutation prediction models can identify which male breast can-
cer (MBC) patients should be offered BRCA1 and BRCA2 diagnostic DNA screening, we com-
pared the performance of BOADICEA (Breast and Ovarian Analysis of Disease Incidence and
Carrier Estimation Algorithm), BRCAPRO (BRCA probability) and the Myriad prevalence table
(“Myriad”). These models were evaluated using the family data of 307 Dutch MBC probands
tested for BRCA1/2, 58 (19%) of whom were carriers. We compared the numbers of observed
vs predicted carriers and assessed the Area Under the Receiver Operating Characteristic (ROC)
Curve (AUC) for each model. BOADICEA predicted the total number of BRCA1/2 mutation car-
riers quite accurately (observed/predicted ratio: 0.94). When a cut-off of 10% and 20% prior
probability was used, BRCAPRO showed a non-significant better performance (observed/pre-
dicted ratio BOADICEA: 0.81, 95% confidence interval [CI]: [0.60-1.09] and 0.79, 95% CI:
[0.57-1.09], vs. BRCAPRO: 1.02, 95% CI: [0.75-1.38] and 0.94, 95% CI: [0.68-1.31], respec-
tively). Myriad underestimated the number of carriers in up to 69% of the cases. BRCAPRO
showed a non-significant, higher AUC than BOADICEA (0.798 vs 0.776). Myriad showed a sig-
nificantly lower AUC (0.671). BRCAPRO and BOADICEA can efficiently identify MBC patients
as BRCA1/2 mutation carriers. Besides their general applicability, these tools will be of particu-
lar value in countries with limited healthcare resources.
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1 | INTRODUCTION
Female carriers of a mutation in BRCA1 (OMIM* 113705) or BRCA2
(OMIM* 600185) are at increased risk of developing breast and ovarian
cancer and require specific clinical management such as extra surveil-
lance and/or preventive surgery and strategies such as platinum-based
therapy1 or PARP inhibitors.2
The cumulative risk of breast cancer at age 70 for male carriers of a
pathogenic BRCA1 or BRCA2 mutation is estimated to be 1.2% and 6.8%,
respectively.3 Male carriers may also be at increased risk for other types
of cancer such as prostate, colon and pancreatic cancer.4,5 Although some
expert groups recommend that male carriers of a pathogenic mutation
should undergo regular mammography in addition to surveillance for pros-
tate cancer, the value of these surveillance strategies is still unproven.6
For these reasons, male mutation carriers generally do not receive extra
surveillance and rarely undergo prophylactic mastectomy of the breasts.
Nonetheless, it is of vital importance to determine whether a male breast
cancer (MBC) patient is a carrier of a pathogenic BRCA1/2 mutation. Not
only is this important as a determinant of chemotherapy choices such as
treatment with platinum1 or PARP inhibitors,2 but also it provides the
opportunity to identify other mutation carriers in the family through cas-
cade screening, thus enabling prevention.
The NICE (National Institute for Health and Care Excellence) guideline
proposes that genetic testing should be offered to female probands when
the combined probability of being a BRCA1 and BRCA2 mutation carrier is
10% or higher.7 However, this guideline is more ambiguous when it comes
to genetic testing for MBC patients. In the Netherlands, every male
affected with breast cancer is offered BRCA1/2 testing regardless of age
or family history. Previous studies have shown that 4%-40% of MBC
patients carry mutations in one of the BRCA genes, with BRCA2mutations
being the most common.8 This obviously means that BRCA1/2 account for
only a minority of MBC patients, and thus many individuals are tested
unnecessarily. As well as being cost-inefficient against a background of lim-
ited healthcare resources, testing may also lead to adverse psychological
effects, as shown for female patients offered BRCA1/2 diagnostic testing.9
Over the last 2 decades, various algorithms, tables and more
sophisticated web-based tools have been developed to calculate the
prior probability of BRCA1 or BRCA2 mutation carriership.10–13
The performance of these models has generally been evaluated in
mostly female probands with various ethnic backgrounds.14–26 We now
wish to establish whether these models can also accurately select MBC
probands for DNA testing. To date, this question has only been
addressed in 2 small studies. In 2010, Zanna et al27 evaluated the dis-
criminatory capacity of the Myriad prevalence table (“Myriad”), the
Ontario Family History Assessment Tool (FHAT), BRCAPRO (BRCA
probability) 4.0 and 5.0 and the Italian Consortium (IC) model in a
cohort of 102 MBC cases from Tuscany, Italy. They found that BRCA-
PRO 5.0 showed the best combination of sensitivity, specificity, nega-
tive predictive value (NPV) and positive predictive value (PPV) for
combined BRCA1/2 probability. BRCAPRO 5.0 was also superior in the
discrimination of BRCA2 mutations and it was especially useful in deal-
ing with non-familial MBC patients. More recently, Mitri et al28 studied
the accuracy of BRCAPRO 6.0 in 146 MBC cases. They concluded that
BRCAPRO is a useful aid in selecting MBC cases for mutation analysis.
Both studies only evaluated the discriminatory ability of the models.
In this study, Myriad,29 BRCAPRO 6.0 (CaGene6) and BOADI-
CEA 3.0 (Breast and Ovarian Analysis of Disease Incidence and Car-
rier Estimation Algorithm) were chosen for evaluation due to their
ability to calculate the mutation prediction probability for an affected
male proband, the frequent (international) use of these tools in both
clinical and research settings, and their free availability. The interna-
tionally known International Breast Cancer Intervention Study (IBIS)
model12 was not used in this study because in IBIS the index case
can only be female.
Including 307 Dutch MBC patients under the age of 80 years, to
the best of our knowledge, the present study is the largest and the
only nationwide study to evaluate the predictive accuracy of several
different mutation carrier probability models. In addition, BOADICEA
has not yet been validated in a population of MBC patients.
The aim of this study was to evaluate the diagnostic accuracy of
these models by investigating and comparing their discriminatory
ability and calibration within a population of MBC patients. We were
interested to know whether these models can accurately predict
mutations in MBC individuals and thus increase diagnostic yield,
opening the way to their use in the selection of MBC cases for DNA
testing in a clinical setting.
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2 | MATERIALS AND METHODS
2.1 | Families
All MBC patients who were diagnosed in the Netherlands between
1989 and 2009 (n = 1487) were identified via the Dutch National
Cancer Registry. Affected males who had been referred for genetic
testing of BRCA1 and BRCA2 to 1 of the 9 genetic cancer centres in
the Netherlands were then used for this study (N = 364). The pedi-
grees and results of genetic testing were collected from the Amster-
dam Medical Centre (AMC, n = 14), Erasmus Medical Centre (EMC,
n = 37), Leiden University Medical Centre (LUMC, n = 40), Maas-
tricht University Medical Centre (MUMC, n = 30), Dutch Cancer
Institute (NKI, n = 28), Radboud University Medical Centre
(RadboudUMC, n = 77), University Medical Centre Groningen
(UMCG, n = 61), University Medical Centre Utrecht (UMCU, n = 44)
and VU University Medical Centre (VUMC, n = 33). From these
families, 57 patients were excluded from the study for the following
reasons: disease or mutation status or pedigree unavailable (n = 23),
the proband was diagnosed with Ductal carcinoma in situ (n = 1),
probands were carriers of a class 2 or 3 variant of uncertain signifi-
cance (VUS). According to the International Agency for Research on
Cancer (IARC) classification they had a posterior probability of path-
ogenicity between 0.1% and 94.9%30 (n = 6). The age at diagnosis
of breast cancer in the proband was above 80 years (cancer diag-
noses that occur after 80 years of age are not included in BOADI-
CEA because of a lack of data to constrain the model) (n = 18).
Nine pedigrees were known in 2 different cancer genetic centres,
so each was included only once.
A final total of 307 cases were included. The proband was always
a male and affected with at least breast cancer. In total 364 of 1487
families (24%) had undergone a DNA test. Table S1, in the Supporting
Information, shows how many probands were tested every year. Data
quality control and imputation rules for missing data are described in
Supporting Information. The collection of data was approved by local
ethics committees.
2.2 | Mutation testing
BRCA1 and BRCA2 mutation analysis was performed at the various
cancer genetics centres in the Netherlands. Diverse mutation screen-
ing methods such as denaturing gradient gel electrophoresis, high-
resolution melting curve analysis, Sanger sequencing and/or multi-
plex ligation-dependent probe amplification were used, followed by
confirmation of aberrant samples by Sanger sequencing. Variant clas-
sification was performed by the molecular clinical geneticists at the
time of the genetic testing, according to internationally recognized
criteria (https://enigmaconsortium.org/wp-content/uploads/2016/
06/ENIGMA_Rules_2015-03-26.pdf, accessed April 2017 and the
Breast cancer core database https://research.nhgri.nih.gov/bic/,
accessed April 2017). VUS were re-evaluated for the present study
and the 6 probands who were carriers of a VUS were excluded from
the study (Clinvar database: [https://www.ncbi.nlm.nih.gov/clinvar/],
accessed April 2017 and LOVD database: [http://databases.lovd.nl/
shared/variants], accessed April 2017).30,31
2.3 | Risk prediction models
The BOADICEA model assumes that genetic susceptibility to breast
cancer is due to BRCA1 and BRCA2 mutations but also takes a poly-
genic component into account.5,10,32 This algorithm allows predicted
mutation probabilities and cancer risks in individuals to be estimated.
Apart from first and second breast and ovarian cancer, it also includes
prostate and pancreatic cancer in the calculations.33 BRCAPRO is a
comparable model which, taking into account family history, calcu-
lates the likelihood of carrying a BRCA1 or BRCA2 gene mutation.34
In this study, we used BOADICEA version 3.0 and BRCAPRO 6.0
(CaGene6). The Myriad tables provide the combined probability of
detecting a BRCA1 and BRCA2 mutation in counselees.29 In contrast
to BOADICEA and BRCAPRO which both provide a continuous num-
ber for the probability of finding a mutation, probabilities in Myriad
for MBC are stratified into specific groups, namely 6.9%, 15.9%,
17.4%, 28.3%, 33.3% and 36.6%.35 The probabilities in these tables
are based on the observation of deleterious mutations in the counse-
lees tested by Myriad Genetics Laboratories. We used the latest ver-
sion of the tables, which was updated in February 2010 and is based
on 162 914 tests.35 The probability that a mutation remained unde-
tected due to limitations of the sequencing technology was taken
into account in the analysis. During the first years of BRCA1/2
screening and up to 2007, a very restricted mutation screening took
place. The average mutation screening sensitivity increased when
modern sequencing technology became available. The mutation
screening sensitivity was assumed to be 95% for all those screened
at and after 2007. For the tests performed before 2007, we used
mutation search sensitivities of 0.7 for BRCA1 and 0.8 for BRCA2.20
2.4 | Statistical evaluation
We evaluated the calibration and discrimination of the risk prediction
models. Calibration tests whether BOADICEA, BRCAPRO and Myriad
can accurately predict the total number of BRCA1 and BRCA2 muta-
tion carriers in the sample set. The calibration of these models was
tested in the whole cohort for different categories of predicted muta-
tion carrier probabilities. To compute the number of mutations pre-
dicted under these models, we averaged the probabilities of
detecting a BRCA1/2 mutation across all families in each category
and then calculated the number of predicted mutation carriers (the
predicted or expected number). Categories with carrier probability
>20% were grouped together because the groups were small. These
were compared with the actual number of mutations detected (the
observed number) by calculating the observed/expected (predicted)
ratio (O/E ratio). The exact 95% confidence intervals (CI) for the O/E
were calculated under a Poisson assumption for the number of
observed mutations.36,37 Discrimination is the ability of the model to
distinguish between a mutation carrier and a non-carrier at the indi-
vidual level. This was assessed using the Area Under the Receiver
Operating Characteristic (ROC) Curve (AUC). Confidence intervals
and tests for comparing AUCs were based on the DeLong et al38
method. Furthermore, we compared the sensitivity, specificity, NPV
and PPV of the models at 10% and 20% carrier probability
thresholds.
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3 | RESULTS
Table 1 shows the characteristics of the 307 probands and families.
Almost 19% of the patients were carrier of either a BRCA1 (2.9%) or
a BRCA2 (16%) mutation. The average age of the onset of breast can-
cer among male carriers was 59.83 years.
3.1 | Calibration
The observed and predicted total number of mutations in each gene
is shown in Table 2. The calibration of BOADICEA in terms of total
number of mutations was better than the other models. Overall,
58 probands were carriers of a pathogenic mutation, whereas BOA-
DICEA predicted 62 mutations (O/E: 0.94, 95% CI: [0.73-1.22]).
BOADICEA predicted 5 BRCA1 and 57 BRCA2 mutation carriers com-
pared with 9 and 49 observed, respectively (O/E ratio for BRCA1:
1.91, 95% CI: [0.99-3.66] and O/E ratio for BRCA2: 0.86, 95% CI:
[0.65-1.14]). For BRCAPRO, the total number of predicted mutations
was lower than observed (58 observed vs 48 predicted, O/E: 1.20,
95% CI: [0.93-1.56]). BRCAPRO predicted 8 BRCA1 and 40 BRCA2
mutation carriers among probands compared with 9 and 49 observed,
respectively (O/E ratio for BRCA1:1.16, 95% CI: [0.61-2.24] and O/E
TABLE 1 Characteristics of the 307 probands and families
Characteristics
Carriers number
(% or mean per family)
Non-carriers number
(% or mean per family)
Probands Carrier of a BRCA1 or BRCA2 mutation 58/307 (18.9%)
BRCA1: 9 (2.9%)
BRCA2: 49 (16%)
249/307 (81%)
Unilateral breast cancer 58 (100%) 249 (100%)
Bilateral breast cancer 5 (8.6%) 8 (3.2%)
Breast cancer and prostate cancer 2 (3.4%) 14 (5.6%)
Average age of onset of breast cancer 59.83 y 60.09 y
Families Unilateral breast cancer in family including proband 202 (3.48) 567 (2.28)
Bilateral breast cancer in family including proband 24 (0.41) 30 (0.12)
Breast cancer and prostate cancer in family including
proband
3 (0.05) 41 (0.16)
Only prostate cancer 11 (0.19) 27 (0.11)
Breast cancer and ovarian cancer in family 0 2 (0.008)
Only ovarian cancer 11 (0.19) 13 (0.05)
TABLE 2 Observed and expected number of mutations by predicted carrier probability
Model
Carrier
probability (%)a
Observed, n Expected, n
O/Eb
95%
Confidence
Interval
No
mutation BRCA1 BRCA2 Either No mutation BRCA1 BRCA2 Either
BOADICEA <5 97 0 6 6 100.31 0.14 2.56 2.69 2.23 1.001-4.96c
5-10 56 2 6 8 59.25 0.23 4.53 4.75 1.68 0.84-3.36
10-15 35 0 2 2 32.43 0.15 4.42 4.57 0.44 0.11-1.75
15-20 12 0 5 5 14.12 0.14 2.74 2.88 1.74 0.72-4.17
>20 49 7 30 37 39.25 4.07 42.68 46.75 0.79 0.57-1.09
Total 249 9 49 58 245.36 4.72 56.91 61.64 0.94 0.73-1.22
BRCAPRO <5 148 2 9 11 155.98 0.30 2.72 3.02 3.65 2.02-6.58c
5-10 51 0 5 5 52.02 0.37 3.61 3.98 1.26 0.52-3.02
10-15 15 0 5 5 17.52 0.21 2.27 2.48 2.02 0.84-4.85
15-20 7 0 2 2 7.45 0.15 1.40 1.55 1.29 0.32-5.17
>20 28 7 28 35 25.86 6.69 30.45 37.14 0.94 0.68-1.31
Total 249 9 49 58 258.83 7.72 40.44 48.17 1.20 0.93-1.56
Myriad <5 0 0 0 0 0 NA NA 0 NA NA
5-10 193 3 23 26 203.89 NA NA 15.11 1.72 1.17-2.53c
10-15 0 0 0 0 0 NA NA 0 NA NA
15-20 44 1 18 19 52.16 NA NA 10.84 1.75 11.12-2.75c
>20 12 5 8 13 16.60 0 0 8.40 1.55 0.90-2.67
Total 249 9 49 58 272.64 NA NA 34.36 1.69 1.30-2.18c
Abbreviations: NA, not available.
a Classes of carrier probability calculated with the respective model.
b Observed/expected (O/E) ratio, observed number of mutation carriers divided by number of mutation carriers expected according to the respective
model.
c The 95% Confidence Interval (CI) for O/E does not include 1.
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ratio for BRCA2: 1.21, 95% CI: [0.92-1.60]). In none of the cases the
difference between O/E ratios was significant. The Myriad tables pro-
vide a combined probability of detecting a BRCA1 or BRCA2 mutation
and underestimated the total number of mutations (58 observed vs
34 predicted, O/E: 1.69, CI: [1.30-2.18]).
3.2 | Discrimination
ROCs are presented in Figure 1 for (A) BOADICEA BRCA1/2, BRCA-
PRO BRCA1/2 and Myriad BRCA1/2, (B) BOADICEA BRCA1 and
BRCAPRO BRCA1, and (C) BOADICEA BRCA2 and BRCAPRO BRCA2.
Corresponding AUCs, or the likelihood that a mutation carrier will
score higher than a non-carrier, are reported in Table 3. A value of
0.5 suggests that the test is no better than tossing a coin and a value
of 1 indicates perfect discriminatory power. The AUC for BOADICEA
was 0.776 (95% CI: [0.708-0.845]), for BRCAPRO it was 0.798 (95%
CI: [0.726-0.871]), and for Myriad it was 0.671 (95% CI: [0.599-
0.743]), the latter being significantly lower than the AUCs for BOADI-
CEA and BRCAPRO (P-value = .0072 for comparison for AUCs of
Myriad and BOADICEA, P-value = .00029 for comparison for AUCs
of Myriad and BRCAPRO). When predicting BRCA1 or BRCA2 muta-
tions separately, BOADICEA and BRCAPRO both showed better dis-
crimination for BRCA1 than for BRCA2 (Table 3). Table 4 shows the
performance of the different models at a carrier probability of 10%
and 20% for BOADICEA and BRCAPRO and the equivalent threshold
score of 6.9 and 17.4 for Myriad. At a 10% threshold, BOADICEA
showed the highest sensitivity (77.2%) and the lowest specificity
(61.4%) for BRCA1 and BRCA2 combined. At a 20% threshold, BOA-
DICEA again had the highest sensitivity (64.9%) and the lowest
specificity (80.3%). At 10% threshold for BRCA1, BOADICEA had a
lower sensitivity compared to BRCAPRO (33.3% vs 55.5%, respec-
tively), however, specificities were comparable (98.7 vs 97.0). At 10%
threshold for BRCA2, sensitivity of BOADICEA was higher than sensi-
tivity of BRCAPRO (75.0% vs 72.9%) while its specificity was lower
(61.2% vs 79.4%). Both models had a lower sensitivity and higher
specificity for BRCA1 compared to BRCA2.
4 | DISCUSSION
Using a cohort consisting of 307 MBC cases assembled from
9 genetic counselling centres, this is the largest study to date to eval-
uate the performance of the 3 most commonly used mutation predic-
tion models, BOADICEA, BRCAPRO and Myriad, in the estimation of
BRCA1 and BRCA2 mutation-carrier probabilities in MBC patients.
We also provide the first validation of the use of BOADICEA in MBC
patients. In contrast to previous studies, we not only studied discrimi-
nation but also examined calibration of the prediction models.
The reported prevalence of BRCA1/2 mutations in MBC patients
varies considerably between different populations and cancer genetic
centres, ranging from 4% to 40% for BRCA2 and up to 4% for BRCA1
genes.8 Our study found that about 19% (58/307) of all MBC
patients actually carry a BRCA mutation. In the Netherlands all
affected male individuals are currently offered BRCA1/2 screening. As
testing all patients might cause unnecessary additional distress in
patients and relatives, a tool that can accurately determine the prior
probability of MBC mutation carriers would therefore be of great
clinical value. Moreover, testing all patients at the moment is cost-
A B C
FIGURE 1 Receiver operating characteristic (ROC) curves. Receiver operator characteristic curves for (A) BOADICEA BRCA1/2, BRCAPRO
BRCA1/2 and Myriad BRCA1/2, (B) BOADICEA BRCA1 and BRCAPRO BRCA1 (C), BOADICEA BRCA2 and BRCAPRO BRCA2, all at 10% cut-off
TABLE 3 Area under the ROC curve for each model
Model
ROC area (95% confidence interval)
Either BRCA1 or BRCA2 BRCA1 BRCA2
BOADICEA 0.776 (0.708-0.845) 0.848 (0.700-0.996) 0.743 (0.667-0.819)
BRCAPRO 0.798 (0.726-0.871) 0.857 (0.708-0.999) 0.768 (0.687-0.849)
Myriad 0.671 (0.599-0.743) NA NA
Abbreviations: NA, not available; ROC curve, receiver operating characteristic curve.
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inefficient, given limited healthcare resources, especially in non-
western countries. However, we acknowledge that, regarding the
price and availability of population-wide gene panel testing, we might
soon be at the stage where it is actually cost-effective to screen all
patients.
Every MBC patient in our study who was referred to a cancer
genetics centre was offered a DNA test, regardless of family history
or the prior probability of being a carrier. However, many of the origi-
nally identified MBC patients (n = 1487, diagnosed between 1989
and 2009) were not referred to cancer genetics centres, primarily
because BRCA1/2 testing was only implemented in clinical practice in
the late 1990's. At that time some clinicians were either unaware of
the possibility of BRCA1/2 testing of male patients or had a different
pattern of referral criteria. It is also possible that in the early years,
clinicians only referred patients with a strong family history or
younger age at diagnosis. The average age for the 307 patients who
were referred is significantly lower than those who were not referred
(60.04 vs 68.06, P-value .0009). Table S1 shows that the number of
BRCA1/2 screenings has increased in recent years. It also shows that
genetic tests were performed in some men several years after their
diagnosis. Studies of the pathological features of BRCA1/2 MBC
tumours showed that these tumours display distinct characteristics
compared with BRCA1/2 female breast cancer tumours (eg, high his-
tologic grade in BRCA2 MBC patients), which suggested greater bio-
logical aggressiveness.39,40 Although it is not directly proven for MBC
caused by BRCA1/2 mutations, it might be the case that some
patients in this specific group were not tested because they did not
survive the disease. These factors partly explain why only 364 pro-
bands among the 1487 MBC patients actually received a DNA test,
and the relatively high percentage of mutation carriers reported in
the study (19%). Although this study is the largest study to date per-
formed for prediction of mutation carrier probability in MBC patients,
it is still a small cohort. The number of patients has limited the power
of this study and as a result, in many cases, the differences are not
significant.
4.1 | Calibration
In our cohort, BOADICEA showed the best calibration for the over-
all number of BRCA1 and BRCA2 mutations. When a cut-off of 10%
and 20% prior probability was used, BRCAPRO showed a non-
significant better performance (observed/predicted ratio BOADICEA:
0.81, 95% CI: [0.60-1.09] and 0.79, 95% CI: [0.57-1.09], vs BRCA-
PRO: 1.02, 95% CI: [0.75-1.38] and 0.94, 95% CI: [0.68-1.31],
respectively).
4.2 | Discrimination
BOADICEA and BRCAPRO both showed good discrimination of
mutation carriers vs non-carriers, whereas Myriad had a significantly
lower AUC. Both BOADICEA and BRCAPRO showed better AUCs
for BRCA1 than for BRCA2, these differences did not, however, reach
statistical significance (P-value = .2187 for comparison of AUCs of
BOADICEA, P-value = .3075 for comparison of AUCs of BRCAPRO).
As BOADICEA and BRCAPRO were developed for female patients it
seems likely that several factors included in these models result in
better prediction of BRCA1 mutations. For example, BRCA1 mutations
are associated with a higher ovarian cancer risk compared to BRCA2
mutations, and with an earlier age at diagnosis of breast cancer.41 As
expected, the number of BRCA1 mutations observed in our cohort
was much lower than the number of BRCA2 mutations (9 vs
49, respectively). This resulted in wide CIs for BRCA1 in both BOADI-
CEA and BRCAPRO (Table 3). Nonetheless, both models showed
good discrimination of BRCA1 and BRCA2 carriers and non-carriers,
although discrimination of carriers of either mutation and of non-
carriers is of limited utility in clinical practice because the overall car-
rier probability determines the decision to screen for mutations. Nev-
ertheless, while probands are always tested simultaneously for
BRCA1 and BRCA2 mutations in the Netherlands, the accurate dis-
crimination of BRCA1 and BRCA2 carriers may be of considerable
importance in countries with fewer financial resources.
TABLE 4 Diagnostic performance of BOADICEA, BRCAPRO and Myriad at different threshold levels
Outcome Cut-off Model Sensitivity (%) Specificity (%) Positive Predictive Value (%) Negative Predictive Value (%)
BRCA1 10% BOADICEA 33.3 98.7 42.9 98.0
BRCAPRO 55.5 97.0 35.7 98.6
Myriad NA NA NA NA
BRCA2 10% BOADICEA 75.0 61.2 26.4 92.9
BRCAPRO 72.9 79. 4 39.7 94.0
Myriad NA NA NA NA
Either BRCA1
or BRCA2
10% BOADICEA 77.2 61.4 31.4 92.1
BRCAPRO 73.7 79.9 45.7 93.0
Myriad (6.9) 54.4 77.5 35.6 88.1
Either BRCA1
or BRCA2
20% BOADICEA 64.9 80.3 43.0 90.9
BRCAPRO 61.4 88.8 55.6 90.9
Myriad (17.4) 22.8 95.2 52.0 84.3
Abbreviation: NA: not available.
Outcome calculated for total and 10% and 20% threshold and equivalent threshold score of 6.9 and 17.4 for Myriad, for BRCA1 or BRCA2 separately if
available, or for both genes.
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In contrast to the Myriad prevalence data, BOADICEA and
BRCAPRO both appear to be well calibrated and show a high discrim-
inatory power to identify male BRCA1/2 mutation carriers. However,
both models could still be improved. At the time of this study, esti-
mates of BRCA1 and BRCA2 mutation frequencies based on a large
Dutch series were unavailable and there were no specific penetrance
estimates for cancers affecting sites other than the breast, so none of
the models included incidence rates for Dutch population. We pre-
sume that incorporating data on Dutch incidences into the models
would improve their accuracy in the present cohort.
Furthermore, the inclusion of other genetic and non-genetic risk
factors known to be important in MBC such as radiation exposure,
alcohol use, obesity, hormonal imbalances, disease and medical treat-
ments leading to hyperestrogenism might also improve the accuracy
of these models.8
5 | CONCLUSION
In the largest cohort of MBC cases studied to date, we found that
BOADICEA and BRCAPRO both showed good discriminatory ability
for male BRCA1/2 carriers. In terms of total number of carriers, BOA-
DICEA showed the best calibration, and BRCAPRO displayed a non-
significant better fit when a mutation probability threshold of 10% or
20% was used. Myriad tables showed a significantly lower calibration
and discrimination compared to the two other models.
Both BOADICEA and BRCAPRO are valuable tools when decid-
ing whether to offer BRCA1 and BRCA2 DNA mutation screening to
MBC patients and will be of considerable value in countries with lim-
ited healthcare resources that cannot offer testing to all MBC
patients. However, both models could potentially be improved
through the incorporation of population-specific parameters and risk
factors for MBC.
BOADICEA is currently the first choice for calculation of muta-
tion carrier probability in many countries42 and the developers are
planning to include other breast cancer-related genes such as PALB2
(OMIM* 610355) and CHEK2 (OMIM+ 604373),43 breast cancer-
associated Single Nucleotide Polymorphism (SNPs), and environmen-
tal factors and risks in the algorithm. A model that incorporates addi-
tional MBC-related factors in a user-friendly tool will eventually be
the preferred choice for the calculation of the mutation carrier proba-
bility in MBC patients.
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